BANKING ANALYTICS

Ranking of the Azerbaijani banking sector (ranking includes the information component of the banking sector, the main events of the world economy, the analytical review of the main indices of the banks which are being ranked)

Iran to manufacture anti-osteoporosis drugs

Iran has announced that it will domestically manufacture the anti-osteoporosis drugs, ISNA reported.

Researchers from the Nasreddin Tusi's Chemical Technology Institute said the Zoledronic acid will now be manufactured in Iran, while earlier it had to be imported into the country.

Zoledronic acid (INN) or zoledronate (marketed by Novartis under the trade names Zometa, Zomera, Aclasta and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.

The price for import of such drugs is estimated at 500 EU, while in Iran the same domestically made drug will cost around $100. The drug will be manufactured by Iranian scientists.